Guggenheim Assumes CRISPR Therapeutics at Neutral

Analyst UpgradesJun 28 19:56

Guggenheim Initiates CRISPR Therapeutics(CRSP.US) With Hold Rating

Guggenheim analyst Debjit Chattopadhyay initiates coverage on $CRISPR Therapeutics(CRSP.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 45.2% and a total average

Futu NewsJun 28 18:31 · Ratings

Intellia Therapeutics Presents Data On Redosing With In Vivo CRISPR Therapy; 55 Mg NTLA-2001 Dose Shows 90% Median Reduction In Serum TTR At Day 28; Well Tolerated Across All Patients; Potential Redosing Advantage For Future Therapies

BenzingaJun 26 03:32

Here's Why We're Not At All Concerned With CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Situation

Simply Wall StJun 20 18:11

CRISPR Therapeutics Stock (NASDAQ:CRSP): Will It Take Off Anytime Soon?

Yahoo FinanceJun 20 02:46

Crispr Therapeutics Price Target Maintained With a $105.00/Share by Piper Sandler

Dow JonesJun 18 01:23